# Clinical Trial Landscape: 15_ovarian_brca1_platinum_sensitive

*Generated: 2026-01-05 07:02:05*

## Summary

- **Total Trials**: 100
- **Flagged for Review**: 0
- **Search Terms Used**: 9

## Phase Distribution

| Phase | Count | Distribution |
|-------|-------|--------------|
| Unknown | 27 | █████ 27.0% |
| Phase 1 | 24 | ████ 24.0% |
| Phase 2 | 22 | ████ 22.0% |
| Not Applicable | 11 | ██ 11.0% |
| Phase 1/Phase 2 | 9 | █ 9.0% |
| Phase 3 | 6 | █ 6.0% |
| Early Phase 1 | 1 |  1.0% |

## Status Distribution

- **Recruiting**: 97 (97.0%)
- **Enrolling by invitation**: 2 (2.0%)
- **Not yet recruiting**: 1 (1.0%)

## Top Sponsors

| Sponsor | Trial Count |
|---------|-------------|
| National Cancer Institute (NCI) | 10 |
| M.D. Anderson Cancer Center | 6 |
| University Health Network, Toronto | 5 |
| McGill University | 3 |
| NRG Oncology | 3 |
| Mayo Clinic | 3 |
| Memorial Sloan Kettering Cancer Center | 2 |
| Abramson Cancer Center at Penn Medicine | 2 |
| Massachusetts General Hospital | 2 |
| AbbVie | 2 |
| Genmab | 2 |
| University of Virginia | 1 |
| Columbia University | 1 |
| Children's Hospitals and Clinics of Minnesota | 1 |
| Johns Hopkins University | 1 |

## Interventions

| Intervention | Occurrences |
|--------------|-------------|
| Biospecimen Collection | 13 |
| Olaparib | 9 |
| Computed Tomography | 9 |
| Magnetic Resonance Imaging | 8 |
| Bevacizumab | 7 |
| Pembrolizumab | 6 |
| Biopsy Procedure | 4 |
| Abemaciclib | 3 |
| Carboplatin | 3 |
| pembrolizumab | 3 |
| Paclitaxel | 3 |
| Niraparib | 3 |
| Biopsy | 3 |
| Blood draw and questionnaires | 2 |
| MRI | 2 |
| Palbociclib | 2 |
| Talazoparib | 2 |
| Futibatinib | 2 |
| Laboratory Biomarker Analysis | 2 |
| cisplatin | 2 |

## Geographic Distribution

| Country | Trial Count |
|---------|-------------|
| United States | 89 |
| Canada | 20 |
| Spain | 14 |
| Australia | 12 |
| France | 12 |
| United Kingdom | 11 |
| Italy | 9 |
| South Korea | 9 |
| Japan | 9 |
| Belgium | 7 |
| Israel | 5 |
| Netherlands | 5 |
| Puerto Rico | 5 |
| Denmark | 3 |
| Sweden | 3 |

## Search Term Provenance

| Term | Source | Confidence |
|------|--------|------------|
| BRCA1 germline mutation | manual | 1.0 |
| ovarian cancer | manual | 1.0 |
| BRCA1 germline mutation ovarian cancer | manual | 1.0 |
| BRCA1 germline mutation high-grade serous ovarian cancer | llm | 0.9 |
| BRCA1 mutation ovarian cancer | llm | 0.9 |
| high-grade serous ovarian cancer | llm | 0.8 |
| Ovarian carcinoma | llm | 0.8 |
| BRCA1 pathogenic variant | llm | 0.9 |
| BRCA1 | llm | 0.9 |

## All Trials

| NCT ID | Phase | Status | Sponsor | Title |
|--------|-------|--------|---------|-------|
| [NCT06654050](https://clinicaltrials.gov/study/NCT06654050) | Phase 2 | Not yet recruiting | National Cancer Inst... | Phase II Study of Alrizomadlin (APG... |
| [NCT06503146](https://clinicaltrials.gov/study/NCT06503146) | Phase 2 | Recruiting | National Cancer Inst... | 18F-Fibroblast Activation Protein I... |
| [NCT06545604](https://clinicaltrials.gov/study/NCT06545604) | Not Applicable | Recruiting | M.D. Anderson Cancer... | Comprehensive Yoga Therapy Based Li... |
| [NCT06580314](https://clinicaltrials.gov/study/NCT06580314) | Phase 3 | Recruiting | NRG Oncology | A Phase III Trial of One vs. Two Ye... |
| [NCT06619236](https://clinicaltrials.gov/study/NCT06619236) | Phase 3 | Recruiting | Genmab | A Phase 3 Randomized, Open-label St... |
| [NCT06617923](https://clinicaltrials.gov/study/NCT06617923) | Phase 2 | Recruiting | Sidney Kimmel Compre... | A Phase 2 Study of Senaparib in Com... |
| [NCT06639074](https://clinicaltrials.gov/study/NCT06639074) | Phase 2 | Recruiting | Mayo Clinic | MC1963 Folate Receptor Alpha Dendri... |
| [NCT06555744](https://clinicaltrials.gov/study/NCT06555744) | Phase 1 | Recruiting | Zymeworks BC Inc. | A Phase 1, Open-label, Multicenter ... |
| [NCT06315491](https://clinicaltrials.gov/study/NCT06315491) | Phase 2 | Recruiting | Cybrexa Therapeutics | A Randomized Phase 2 Study of CBX 1... |
| [NCT06476808](https://clinicaltrials.gov/study/NCT06476808) | Phase 1 | Recruiting | Bristol-Myers Squibb | A Phase 1/1b First-in-human Study o... |
| [NCT06582017](https://clinicaltrials.gov/study/NCT06582017) | Phase 1 | Recruiting | Nammi Therapeutics I... | A First-in-human Phase 1a/1b Study ... |
| [NCT06504147](https://clinicaltrials.gov/study/NCT06504147) | Phase 2 | Recruiting | Oncoinvent AS | A Phase 2, Randomised, Open Label, ... |
| [NCT06459271](https://clinicaltrials.gov/study/NCT06459271) | Not Applicable | Recruiting | University Health Ne... | A Feasibility Trial of Managing Can... |
| [NCT06451497](https://clinicaltrials.gov/study/NCT06451497) | Phase 1 | Recruiting | Zumutor Biologics In... | Phase 1 Dose Escalation Trial of ZM... |
| [NCT06400472](https://clinicaltrials.gov/study/NCT06400472) | Phase 1 | Recruiting | Eli Lilly and Compan... | A First-in-Human, Phase 1a/1b Trial... |
| [NCT06395519](https://clinicaltrials.gov/study/NCT06395519) | Phase 1/Phase 2 | Recruiting | 858 Therapeutics, In... | A Study of PARG Inhibitor ETX-19477... |
| [NCT06257264](https://clinicaltrials.gov/study/NCT06257264) | Phase 1 | Recruiting | BeiGene | A Phase 1a/1b Study of BG-68501, a ... |
| [NCT05806515](https://clinicaltrials.gov/study/NCT05806515) | Phase 2 | Recruiting | SWOG Cancer Research... | S2210 A Phase II Study of Neoadjuva... |
| [NCT06177171](https://clinicaltrials.gov/study/NCT06177171) | Phase 1 | Recruiting | Pamela Munster | A Phase I/Ib Study of Olaparib and ... |
| [NCT05950282](https://clinicaltrials.gov/study/NCT05950282) | N/A | Recruiting | Lilli Health | Measuring Fasting Insulin and HOMA-... |
| [NCT06659614](https://clinicaltrials.gov/study/NCT06659614) | N/A | Recruiting | Abramson Cancer Cent... | Prostate Tissue Biobank for People ... |
| [NCT05950464](https://clinicaltrials.gov/study/NCT05950464) | Phase 1 | Recruiting | National Cancer Inst... | A Phase 1B Study of Combination ATR... |
| [NCT06083844](https://clinicaltrials.gov/study/NCT06083844) | Phase 2 | Recruiting | M.D. Anderson Cancer... | Phase II Investigation of Pembroliz... |
| [NCT06188520](https://clinicaltrials.gov/study/NCT06188520) | Phase 1/Phase 2 | Recruiting | AstraZeneca | A Phase I/IIa, First-in-human, Open... |
| [NCT06108479](https://clinicaltrials.gov/study/NCT06108479) | Phase 1 | Recruiting | Dragonfly Therapeuti... | A Phase I/Ib, First-In-Human, Multi... |
| [NCT05998135](https://clinicaltrials.gov/study/NCT05998135) | Phase 2 | Recruiting | Emory University | Phase II Clinical Trial Repurposing... |
| [NCT05902988](https://clinicaltrials.gov/study/NCT05902988) | Phase 1/Phase 2 | Recruiting | Volastra Therapeutic... | A Phase I/II Study of VLS-1488 (an ... |
| [NCT05752448](https://clinicaltrials.gov/study/NCT05752448) | Not Applicable | Recruiting | Baylor College of Me... | POSTCARE-O: Survivorship Care for W... |
| [NCT05920798](https://clinicaltrials.gov/study/NCT05920798) | Phase 1/Phase 2 | Recruiting | Mayo Clinic | MC220601, Folate Receptor Alpha Den... |
| [NCT05989724](https://clinicaltrials.gov/study/NCT05989724) | Phase 1 | Recruiting | Qurgen Inc. | A First-in-Human (FIH), Open-Label,... |
| [NCT05879926](https://clinicaltrials.gov/study/NCT05879926) | Phase 3 | Recruiting | NRG Oncology | A Phase III Adjuvant Trial Evaluati... |
| [NCT05961124](https://clinicaltrials.gov/study/NCT05961124) | Phase 2 | Recruiting | Sunnybrook Health Sc... | A Phase II, Single-Arm Trial Assess... |
| [NCT05694715](https://clinicaltrials.gov/study/NCT05694715) | Phase 1 | Recruiting | University of Califo... | Combination Therapy of Niraparib an... |
| [NCT05746897](https://clinicaltrials.gov/study/NCT05746897) | Phase 1 | Recruiting | Hefei TG ImmunoPharm... | A Phase 1 Study to Investigate the ... |
| [NCT05787587](https://clinicaltrials.gov/study/NCT05787587) | Phase 1 | Recruiting | IDEAYA Biosciences | A Study of PARG Inhibitor IDE161 in... |
| [NCT05827614](https://clinicaltrials.gov/study/NCT05827614) | Phase 1 | Recruiting | Boundless Bio | An Open-Label, Multicenter, First-i... |
| [NCT05720117](https://clinicaltrials.gov/study/NCT05720117) | Phase 1 | Recruiting | Pyxis Oncology, Inc | A First-in-Human, Open-label, Multi... |
| [NCT05065021](https://clinicaltrials.gov/study/NCT05065021) | Phase 2 | Recruiting | University Health Ne... | Re-VOLVE: A Phase II Clinical Trial... |
| [NCT05512208](https://clinicaltrials.gov/study/NCT05512208) | Phase 2 | Recruiting | University of Oklaho... | A Phase 2 Study of VS-6766 (Dual RA... |
| [NCT05498272](https://clinicaltrials.gov/study/NCT05498272) | Phase 2 | Recruiting | Rana McKay, MD | A Phase 2 Study of Neoadjuvant PARP... |
| [NCT05527184](https://clinicaltrials.gov/study/NCT05527184) | Phase 1 | Recruiting | AbbVie | A Phase 1, First-in-Human, Open-Lab... |
| [NCT05625529](https://clinicaltrials.gov/study/NCT05625529) | N/A | Recruiting | Biological Dynamics | Exoluminate Study: Observational Re... |
| [NCT05579366](https://clinicaltrials.gov/study/NCT05579366) | Phase 1/Phase 2 | Recruiting | Genmab | Phase 1/2 Study of Rina-S in Patien... |
| [NCT05327010](https://clinicaltrials.gov/study/NCT05327010) | Phase 2 | Recruiting | National Cancer Inst... | Phase 2 Trial of the Combination of... |
| [NCT05281471](https://clinicaltrials.gov/study/NCT05281471) | Phase 3 | Recruiting | Genelux Corporation | A Randomized Phase 3 Study Assessin... |
| [NCT05300711](https://clinicaltrials.gov/study/NCT05300711) | Not Applicable | Recruiting | University of Britis... | Preventing Ovarian Cancer Through t... |
| [NCT05429970](https://clinicaltrials.gov/study/NCT05429970) | Not Applicable | Recruiting | Memorial Sloan Kette... | Perioperative Stress Reduction in O... |
| [NCT05287451](https://clinicaltrials.gov/study/NCT05287451) | Not Applicable | Recruiting | M.D. Anderson Cancer... | Risk Reducing Salpingectomy With De... |
| [NCT04918186](https://clinicaltrials.gov/study/NCT04918186) | Phase 2 | Recruiting | Canadian Cancer Tria... | An Immunotherapy Platform Study in ... |
| [NCT05277051](https://clinicaltrials.gov/study/NCT05277051) | Phase 1 | Recruiting | GlaxoSmithKline | A Phase 1 First-Time-in-Human, Open... |

*... and 50 more trials (see trials.csv for full list)*
